Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Status:
Active, not recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety and tolerability of
abemaciclib when given in combination with darolutamide to participants with prostate cancer
that has spread after initial treatment. Participation may last up to 32 months.